highly significantp =0.0008
19 , 20 In the phase III randomized controlled “OPTiM” trial, subgroup analysis revealed a highly significant survival improvement for American Joint Committee on Cancer (AJCC) stage IIIB-IVM1a patients (46.8 months vs 21.5 months; p =0.0008), but no significant benefit for AJCC stages IVM1b/c patients. 21 In this study T-VEC had a tolerable safety profile with a low rate of treatment-related grade 3–4 adverse events (AE), which occurred in 11.3%. 21 The most common AEs were fatigue, chills, pyrexia, nausea and influenza-like illness. 21 These data indicate that T-VEC could be a good therapy option, especially in old and oldest-old patients.